Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, enhancing COPD treatment and expanding global growth ...

The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

GSK has signed a $500 million upfront licensing deal with Jiangsu Hengrui to secure global rights to its COPD drug HRS‑9821 ...

London: GSK plc has announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to 12 ...

GSK plc has entered into agreements with China-based biotechnology company Hengrui Pharma to develop up to 12 innovative ...

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

Hengrui Pharma (600276.SH; 01276.HK) today announced it has entered into agreements with GSK plc (LSE/NYSE: GSK) to develop up to 12 innovative medicines, adding significant value to the globalization ...